Rating Change: Revance Therapeutics (RVNC): What Aegis Capital Is Saying; Why Has $28.0 Stock Target

November 29, 2016 - By Hazel Jackson

Rating Change: Revance Therapeutics (RVNC): What Aegis Capital Is Saying; Why Has $28.0 Stock Target

Why Aegis Capital Gives Revance Therapeutics (RVNC) $28.0 Price Target

Expert analysts at Aegis Capital has begun coverage on Revance Therapeutics (RVNC) with a Buy rating. The target price per share for RVNC is $28.0. It suggests a potential upside of 59.09% from firm’s close price.

About 48,665 shares traded hands. Revance Therapeutics Inc (RVNC) has declined 10.61% since April 26, 2016 and is downtrending. It has underperformed by 15.87% the S&P500.

Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on March, 1. They expect $-0.88 earnings per share, down 6.02% or $0.05 from last year’s $-0.83 per share. After $-0.64 actual earnings per share reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts 37.50% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 0.89 in 2016 Q2. Its down 0.50, from 1.39 in 2016Q1. The ratio worsened, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.

State Street Corp has 0% invested in the company for 429,482 shares. Legal And General Gru Pcl accumulated 0% or 3,561 shares. The California-based Blackrock Fund Advsr has invested 0% in Revance Therapeutics Inc (NASDAQ:RVNC). Rhumbline Advisers has 0% invested in the company for 19,030 shares. Fincl Bank Va reported 77,177 shares or 1.04% of all its holdings. Deutsche Bancorporation Ag has invested 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC). Bnp Paribas Arbitrage Sa accumulated 980 shares or 0% of the stock. Parametric Associate Llc last reported 21,068 shares in the company. Iguana Health Mngmt Lc last reported 100,000 shares in the company. Wells Fargo Communication Mn has invested 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC). Schwab Charles Mngmt accumulated 0% or 66,263 shares. Blackrock Institutional Trust Communication Na accumulated 0% or 514,939 shares. Lombard Odier Asset Management (Usa), a New York-based fund reported 22,515 shares. State Of New Jersey Common Pension Fund D has 26,000 shares for 0% of their US portfolio. Arrowpoint Asset Limited Liability accumulated 0.46% or 1.67 million shares.

Insider Transactions: Since June 13, 2016, the stock had 0 insider buys, and 3 sales for $411,454 net activity. The insider Browne L Daniel sold $215,005. $18,250 worth of Revance Therapeutics Inc (NASDAQ:RVNC) was sold by Ruegg Curtis.

Revance Therapeutics, Inc. is a biotechnology company. The company has a market cap of $492.11 million. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. It currently has negative earnings. The Company’s TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel , or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

According to Zacks Investment Research, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.”

RVNC Company Profile

Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.

Another recent and important Revance Therapeutics Inc (NASDAQ:RVNC) news was published by Fool.com which published an article titled: “Why Revance Therapeutics Is Crashing 23% Today” on June 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>